These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 3188531)
1. [Prostatic cancer in the male under age 60]. Maier U; Nuehold N Wien Klin Wochenschr; 1988 Sep; 100(17):577-9. PubMed ID: 3188531 [TBL] [Abstract][Full Text] [Related]
2. Primary metastatic carcinoma of the prostate in younger men: a plea to think over usual therapeutic strategies. Maier U; Höbarth K; Simak R Eur Urol; 1996; 29(2):221-3. PubMed ID: 8647151 [TBL] [Abstract][Full Text] [Related]
3. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898 [TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Pummer K; Lehnert M; Stettner H; Hubmer G Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791 [TBL] [Abstract][Full Text] [Related]
6. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303 [TBL] [Abstract][Full Text] [Related]
7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
8. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136 [TBL] [Abstract][Full Text] [Related]
9. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E; Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865 [TBL] [Abstract][Full Text] [Related]
10. [What is safe in the therapy of advanced prostatic cancer?]. Gropp C; Burk K Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819 [No Abstract] [Full Text] [Related]
11. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426 [TBL] [Abstract][Full Text] [Related]